Europe & Central Asia

Afghanistan
Decades of conflict have ruined Afghanistan’s economy and infrastructure and many people rely on humanitarian aid.
130,500
Outpatient consultations36,300
Births assisted6,990
Surgical interventions1,370
People started on treatment for TB600
Patients admitted for COVID-19
Albania
MSF first worked in Albania in 1998 and closed its projects in 2000.

Armenia
In Armenia, MSF first worked in the country in 1988 to respond to medical needs following the Spitak earthquake, before treating people with drug-resistant tuberculosis with new, effective drugs. We closed our last projects in 2019.

Azerbaijan
After working in Azerbaijan for more than ten years, MSF closed its last projects in 2003.

Belarus
We are working with the Ministry of Health in Belarus to improve adherence to treatment for patients with multidrug-resistant tuberculosis (MDR-TB).
43
People started on treatment for DR-TB
Belgium
In Belgium, MSF teams work with migrants and refugees, and are working in nursing homes and with homeless people in response to the COVID-19 pandemic.
260
patients admitted for COVID-1996
outpatient consultations for COVID-19
Bosnia and Herzegovina
After a decade working with populations affected by the Balkan wars, we ended our work in Bosnia and Herzegovina in 2001. In 2018, we returned to assist migrants and refugees escaping war and persecution in the Middle East, Asia and Africa.
3,460
outpatient consultations180
people treated for intentional physical violence140
individual mental health consultations
Bulgaria
MSF first worked in Bulgaria in 1981 and closed its projects in 2015.

Croatia
MSF closed its projects in Croatia in 1998.

France
In Paris, northern France and at the borders with Italy and Spain, migrants and refugees encounter policies and practices aimed at preventing them from settling or claiming their rights.
1,950
individual mental health consultations
Georgia
MSF began working in Georgia in 1993 to deliver healthcare to people affected by internal displacement and conflict, before providing treatment to people with multidrug-resistant tuberculosis (MDR-TB).
